Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 23

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 23
---
 attractive for markets on the
Pacific Rim, South Asia and South America, but will wait for partners to help with the development in those regions, however, at this
time, we are not negotiating with any potential partners.

Importantly, we have published
data demonstrating INKmune efficacy at priming allogeneic NK cells ex-vivo (described above) and this includes priming of NK cells differentiated
from cord-blood derived hematopoietic stem cells (Domogala et al Cytotherapy 2017: 19:710-720). Numerous companies are developing
therapeutic strategies using cord blood derived NK cell products and one or more may wish to partner with us to potentiate their product
by co-incubation or co-administration with INKmune. We are also aware of companies developing cytokine primed NK cells (CIML) for the
treatment of cancer. We believe tumor primed NK cells are superior to ex vivo or in vivo cytokine strategies.

Challenges in the Market for Our Product Candidates

The market for new oncology
therapies is competitive, complicated, and rapidly evolving. We will be competing with companies that are older, larger, better financed
and have greater experience. There are two types of drug companies – development companies and commercial companies. Development
companies take the risk of developing new products to proof-of-concept. Once proof-of-concept has been achieved, if the drug provides
clinical benefit, the product is usually acquired by a commercial company, which completes the drug’s clinical development and markets
the product. We are a development company which will seek to develop products such as INKmune from the bench to the bedside to demonstrate
proof-of-concept. The goal for us is to successfully develop such products to the point where they are attractive targets for potential
partners/acquirers.

According to a recent Markets
and Markets report, the immunotherapy market is growing rapidly at an annual rate of over 13%. Recently, the market is biased towards
T cell-based immunotherapies including bi-specific antibody therapies, checkpoint inhibitors and CAR-T cell-based therapies. There are
substantial numbers of clinical trials that are focused on the adaptive immune system versus clinical trials that are focused on the innate
immune system for the treatment of cancer. Our challenge will be to educate partners on the value of NK cell-based therapeutic strategies.
The need to educate people of the importance of INB03 is equally challenging. At the academic and investor